

Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in *Nicotiana benthamiana*)

Catalog No. NR-52392

This reagent is the property of the U.S. Government.

For research use only. Not for use in humans.

Contributor and Manufacturer:

Novici Biotech LLC, Vacaville, California, USA

Product Description:

Antibody Class: IgG1

Human monoclonal antibody CR3022 was prepared via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient.^{1,2} CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV.² NR-52392 was produced in *Nicotiana benthamiana* tobacco plants using a transient plant expression system and purified from the extracellular fraction using protein A chromatography.¹ Plant-made antibody CR3022 features complementarity-determining region (CDR) sequences introduced into a human IgG1 molecule.^{1,3} The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV.³

Note: Questions related to NR-52392 may be addressed by contacting info@novicibiotech.com.

Material Provided:

Each vial of NR-52392 contains approximately 50 µL of purified monoclonal antibody in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-52392 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -60°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-52392 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV.^{1,2} CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in Western blot analysis; however, CR3022 did not neutralize SARS-CoV-2 in a recent *in vitro* assay.^{1,3} CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and biolayer interferometry (BLI) binding assays.⁴

Applications: Western blot analysis, immunofluorescence, ELISA and neutralization.^{1,2,3,4}

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in *Nicotiana benthamiana*), NR-52392."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Padgett, H. S., Personal Communication.

2. Ter Meulen, J., et al. "Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants." PLoS Med. 3 (2006): e237. PubMed: 16796401.
3. Yuan, M., et al. "A Highly Conserved Cryptic Epitope in the Receptor-Binding Domains of SARS-CoV-2 and SARS-CoV." Science 368 (2020): 630-633. PubMed: 32245784.
4. Tian, X., et al. "Potent Binding of 2019 Novel Coronavirus Spike Protein by a SARS Coronavirus-Specific Human Monoclonal Antibody." Emerg. Microbes Infect. 9 (2020): 382-385. PubMed: 32065055.

ATCC® is a trademark of the American Type Culture Collection.

